Piper Sandler Reiterates Overweight on Arrowhead Pharma, Raises Price Target to $126
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst Edward Tenthoff reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $110 to $126.
Piper Sandler analyst Edward Tenthoff reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $110 to $126.